These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 37229173)
1. Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma. Lu X; Green BL; Xie C; Liu C; Chen X JHEP Rep; 2023 Jul; 5(7):100723. PubMed ID: 37229173 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers. Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970 [TBL] [Abstract][Full Text] [Related]
3. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma. Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957 [TBL] [Abstract][Full Text] [Related]
10. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. Rimassa L; Personeni N; Aghemo A; Lleo A J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450 [TBL] [Abstract][Full Text] [Related]
11. The role of tumour microenvironment: a new vision for cholangiocarcinoma. Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682 [TBL] [Abstract][Full Text] [Related]
12. Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma. Zhao LM; Shi AD; Yang Y; Liu ZL; Hu XQ; Shu LZ; Tang YC; Zhang ZL Front Oncol; 2023; 13():1140103. PubMed ID: 37064120 [TBL] [Abstract][Full Text] [Related]
13. The State of Immunotherapy in Hepatobiliary Cancers. Ilyas FZ; Beane JD; Pawlik TM Cells; 2021 Aug; 10(8):. PubMed ID: 34440865 [TBL] [Abstract][Full Text] [Related]
14. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches. Vatankhah F; Salimi N; Khalaji A; Baradaran B Int Immunopharmacol; 2023 Jan; 114():109526. PubMed ID: 36481527 [TBL] [Abstract][Full Text] [Related]
15. Advances in Targeted Immunotherapy for Hepatobiliary Cancers. Ruff SM; Shannon AH; Pawlik TM Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440 [TBL] [Abstract][Full Text] [Related]
16. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma. Lodl E; Ramnaraign B; Sahin I; Wheeler S J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888 [TBL] [Abstract][Full Text] [Related]
17. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma. Shang T; Jiang T; Lu T; Wang H; Cui X; Pan Y; Xu M; Pei M; Ding Z; Feng X; Lin Y; Li X; Tan Y; Feng F; Dong H; Wang H; Dong L Front Immunol; 2023; 14():1166497. PubMed ID: 37234171 [TBL] [Abstract][Full Text] [Related]
18. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Elvevi A; Laffusa A; Scaravaglio M; Rossi RE; Longarini R; Stagno AM; Cristoferi L; Ciaccio A; Cortinovis DL; Invernizzi P; Massironi S Ann Hepatol; 2022; 27(5):100737. PubMed ID: 35809836 [TBL] [Abstract][Full Text] [Related]
19. Precision Medicine in Cholangiocarcinoma: Past, Present, and Future. Cheng CY; Chen CP; Wu CE Life (Basel); 2022 Jun; 12(6):. PubMed ID: 35743860 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for cholangiocarcinoma: a 2021 update. Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]